The prognostic value of 18F-FDG PET/CT intra-tumoural metabolic heterogeneity in pretreatment neuroblastoma patients

Table 4 Comparison of AUC-CSH_total and AUC-CSH_40% between different subgroups

Variable		AUC-CSH_40%	P	AUC-CSH_total	P
COG			0.965		0.018*
	Low and medium risk	0.560±0.060		0.506±0.108
	High risk	0.561±0.039		0.431±0.079
BMI
	No	0.563±0.070	0.914	0.516±0.113	0.030*
	Yes	0.560±0.038		0.441±0.007
MYCN
	Normal	0.560±0.054	0.947	0.465±0.113	0.861
	Acquired and amplify	0.561±0.039		0.459±0.077
EFS
	Without event	0.581±0.049	0.009*	0.515±0.101	<0.001*
	With event	0.541±0.039		0.410±0.062

COG Children's Oncology Group, BMI bone morrow involvement, MYCN myelocytomatosis viral oncogene neuroblastoma derived homolog, EFS event-free survival, AUC-CSH areas under the curve of cumulative SUV-volume histogram, *P < 0.05

ISSN: 1470-7330